Literature DB >> 28584145

Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.

Carlota Gudiol1,2,3, Cristina Royo-Cebrecos4,3, Edson Abdala5, Murat Akova6, Rocío Álvarez7, Guillermo Maestro-de la Calle8, Angela Cano9,3, Carlos Cervera10, Wanessa T Clemente11, Pilar Martín-Dávila12, Alison Freifeld13, Lucía Gómez14, Thomas Gottlieb15, Mercè Gurguí16, Fabián Herrera17, Adriana Manzur18, Georg Maschmeyer19, Yolanda Meije20,3, Miguel Montejo21,3, Maddalena Peghin22, Jesús Rodríguez-Baño23,3, Isabel Ruiz-Camps24,3, Teresa C Sukiennik25, Cristian Tebe26, Jordi Carratalà4,3.   

Abstract

β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ESBLs; beta-lactam/beta-lactamase inhibitors; bloodstream infection; mortality; neutropenia

Mesh：

Substances：

Year:  2017        PMID： 28584145      PMCID： PMC5527609          DOI： 10.1128/AAC.00164-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015.

Authors:  Barbara Albiger; Corinna Glasner; Marc J Struelens; Hajo Grundmann; Dominique L Monnet
Journal:  Euro Surveill       Date:  2015

2.  β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

Authors:  Jesús Rodríguez-Baño; María Dolores Navarro; Pilar Retamar; Encarnación Picón; Álvaro Pascual
Journal:  Clin Infect Dis       Date:  2011-11-04       Impact factor: 9.079

3.  Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.

Authors:  Si-Hyun Kim; Jae-Cheol Kwon; Su-Mi Choi; Dong-Gun Lee; Sun Hee Park; Jung-Hyun Choi; Jin-Hong Yoo; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Hee-Je Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min
Journal:  Ann Hematol       Date:  2012-11-17       Impact factor: 3.673

4.  Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.

Authors:  Hsih-Yeh Tsai; Yen-Hsu Chen; Hung-Jen Tang; Chi-Chang Huang; Chun-Hsing Liao; Fang-Yeh Chu; Yin-Ching Chuang; Wang-Huei Sheng; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Diagn Microbiol Infect Dis       Date:  2014-07-26       Impact factor: 2.803

5.  Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.

Authors:  Enrico M Trecarichi; Mario Tumbarello; Teresa Spanu; Morena Caira; Luana Fianchi; Patrizia Chiusolo; Giovanni Fadda; Giuseppe Leone; Roberto Cauda; Livio Pagano
Journal:  J Infect       Date:  2009-03-09       Impact factor: 6.072

6.  Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia.

Authors:  Michael Y Lin; Robert A Weinstein; Bala Hota
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

7.  Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies.

Authors:  Michael J Satlin; David P Calfee; Liang Chen; Kathy A Fauntleroy; Stephen J Wilson; Stephen G Jenkins; Eric J Feldman; Gail J Roboz; Tsiporah B Shore; David C Helfgott; Rosemary Soave; Barry N Kreiswirth; Thomas J Walsh
Journal:  Leuk Lymphoma       Date:  2012-09-14

Review 8.  Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.

Authors:  Konstantinos Z Vardakas; Giannoula S Tansarli; Petros I Rafailidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2012-08-21       Impact factor: 5.790

9.  Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Authors:  Tat Ming Ng; Wendy X Khong; Patrick N A Harris; Partha P De; Angela Chow; Paul A Tambyah; David C Lye
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

10.  Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).

Authors:  C Gudiol; C Royo-Cebrecos; C Tebe; E Abdala; M Akova; R Álvarez; G Maestro-de la Calle; A Cano; C Cervera; W T Clemente; P Martín-Dávila; A Freifeld; L Gómez; T Gottlieb; M Gurguí; F Herrera; A Manzur; G Maschmeyer; Y Meije; M Montejo; M Peghin; J Rodríguez-Baño; I Ruiz-Camps; T C Sukiennik; J Carratalà
Journal:  BMJ Open       Date:  2017-01-23       Impact factor: 2.692
View more
  17 in total

1.  Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy.

Authors:  Grace E Benanti; Anne Rain T Brown; Terri Lynn Shigle; Jeffrey J Tarrand; Micah M Bhatti; Patrick M McDaneld; Samuel A Shelburne; Samuel L Aitken
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.

Authors:  Michael J Satlin; Kalyan D Chavda; Thomas M Baker; Liang Chen; Elena Shashkina; Rosemary Soave; Catherine B Small; Samantha E Jacobs; Tsiporah B Shore; Koen van Besien; Lars F Westblade; Audrey N Schuetz; Vance G Fowler; Stephen G Jenkins; Thomas J Walsh; Barry N Kreiswirth
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

Review 3.  Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms.

Authors:  Audrey N Schuetz; Sergio Reyes; Pranita D Tamma
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

4.  Evaluation of the Accelerate Pheno™ system for rapid identification and antimicrobial susceptibility testing of Gram-negative bacteria in bloodstream infections.

Authors:  Ghislaine Descours; Laurent Desmurs; Thi Lam Thuy Hoang; Marine Ibranosyan; Maud Baume; Anne-Gaëlle Ranc; Christine Fuhrmann; Olivier Dauwalder; Waël Salka; François Vandenesch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-28       Impact factor: 3.267

Review 5.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

6.  Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population.

Authors:  Pranita D Tamma; Maria Virginia Villegas
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016.

Authors:  Tingting Xiao; Kai Yang; Yanzi Zhou; Shuntian Zhang; Jinru Ji; Chaoqun Ying; Ping Shen; Yonghong Xiao
Journal:  Antimicrob Resist Infect Control       Date:  2019-08-27       Impact factor: 4.887

Review 8.  Update on the management of febrile neutropenia in hematologic patients.

Authors:  F Escrihuela-Vidal; J Laporte; A Albasanz-Puig; C Gudiol
Journal:  Rev Esp Quimioter       Date:  2019-09       Impact factor: 1.553

9.  Point prevalence surveys of antimicrobial use among eight neonatal intensive care units in India: 2016.

Authors:  Sumanth Gandra; Gerardo Alvarez-Uria; Srinivas Murki; Sanjeev K Singh; Ravishankar Kanithi; Dasaratha R Jinka; Ashok K Chikkappa; Sreeram Subramanian; Anita Sharma; Dhanya Dharmapalan; Hemasree Kandraju; Anil Kumar Vasudevan; Onkaraiah Tunga; Akhila Akula; Yingfen Hsia; Mike Sharland; Ramanan Laxminarayan
Journal:  Int J Infect Dis       Date:  2018-03-30       Impact factor: 3.623

10.  Update in Infectious Diseases 2018.

Authors:  F J Candel; T Emilov; I Diaz de la Torre; A Ruedas; J M Viñuela Prieto; C Visiedo; J Martínez-Jordán; L López-González; M Matesanz; A Arribi
Journal:  Rev Esp Quimioter       Date:  2018-09       Impact factor: 1.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.